Review on Effects of NSAID`S on Different Systems

  • Naresh Puppala Department of Pharmacy Practice, Jyothishmathi Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India
  • Gantala Alekhya Reddy Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

Abstract

Non steroidal anti-inflammatory drugs (NSAIDs) are amongst the most commonly prescribed medication. Some are available over the counter and likely to be abused. The gastrointestinal (GI), renal and cardiovascular (CV) side effects limit NSAIDs use. These side effects occurred at a rate as low as 1%–5% for NSAID users. The gastrointestinal (GI), renal and cardiovascular (CV) side effects limit NSAIDs use. Some studies  have shown  that an extra 2to8 per 1000 people per year may have a major vascular event from using an NSAID. Several studies demonstrated that conventional NSAIDs were associated with a higher risk of AKI and GN and decreased kidney hemodynamic functions, including sodium excretion. NSAIDs have a range of adverse effects mainly affecting the GI, renal and CV systems.


 

Keywords: Nonsteroidal, anti-inflammatory drugs, inflammation, cyclooxygenase enzymes

Downloads

Download data is not yet available.

Author Biographies

Naresh Puppala, Department of Pharmacy Practice, Jyothishmathi Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

Department of Pharmacy Practice, Jyothishmathi Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

Gantala Alekhya Reddy, Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

References

1. Rivosecchi RM,KellumJA,DastaJF,ArmahizerMJ,BolestaS,Buckley MS, Dzierba AL, Frazee EN, Johnson HJ, Kim C, Murugan R, Smithburger PL, Wong A, Kane Gill SL: Drug class combination-associated acute kidney injury. Ann Pharmacother,2016; 50: 953–972, 2016
2. Garella S, Matarese RA. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine 1984; 63:165-81.
3. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Eng J Med 1984; 310:563-72.
4. Sedor JR, Davidson EW, Dunn MJ. Effects of nonsteroidal anti-inflammatory drugs in healthy subjects. Am J Med 1986; 81:58-70.
5. Levin ML. Patterns of tubulointerstitial damage associated with non-steroidal anti-inflammatory drugs. Semin Nephrol 1988; 8:55-61
6. Kleinknecht D. Interstitial nephritis, the nephritic syndrome and chronic renal failure secondary to non-steroidal antiinflammatory drugs. Semin Nephrol 1995; 15:228-35.
7. Whelton A. Nephrotoxicity of nonsteroidal antiinflammatory drugs: Physiologic foundations and clinical implications. Am J Med 1999; 106:13S-24S.
8. Blackshear JL, Napier JS, Davidman M, Stillman MT. Renal complications of nonsteroidal anti-inflammatory drugs: Identification and monitoring of those at risk. Semin Arthritis Rheum 1985; 14:165-75.
9. Tse WY, Adu D. Non-steroidal anti-inflammatory drugs and the kidney. In : Davison AM, Cameron S, Grunfeld JP, Kerr DNB, Ritz E, Winerals CG, eds, Oxford textbook of nephrology, 2nd Edition, Oxford publications, 1998:114556.
10. Harirforoosh S, Jamali F. Renal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009; 8(6):669-81.
11. Knights KM, Winner LK, Elliot DJ, Bowalgaha K, Miners JO. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDPglucuronosyltransferases: inhibition by NSAIDs. Britj Clin Pharmacol. 2009; 68(3):402-12.
12. Ritter JK. Roles of glucuronidation and UDPglucuronosyltransferases in xenobiotic bioactivation reactions. Chemico-biologl interac 2000; 1; 129(1-2):171-93.
13. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis. 1996; 28(1 Suppl 1):S56-62.
14. Essex MN, Zhang RY, Berger MF, Upadhyay S, park PW.Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials. Expert Opin Drug Safety. 2013;12(4):465-77.
15. Segal R, Lubart E, Leibovitz A, Iaina A, Caspi D: Renal effects of low dose aspirin in elderly patients. Isr Med Assoc J 8: 679–682, 2006
16. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med 1999; 106[5B]: 13S–24S,
17. Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ1995; 311:222–6.
18. Langman MJS. Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden? Pharmacoepidemiol Drug Safety 2001; 10:13–19.
19. Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs. 2003; 63(6):525-34.
20. McGettigan P, Henry D. Use of non-steroidal antiinflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS medicine. 2013; 10(2):e1001388.
21. Farker K, Merkel U, Schweer H, Haerting J, Madani SF, Eggers R, Mu ¨ller UA, Seyberth HW, Hoffmann A: Effects of short-term treatment with diclofenac-colestyramine on renal function and urinary prostanoid excretion in patients with type-2diabetes.EurJ Clin Pharmacol 2002; 58: 85–91.
22. Cohen HJ, Walston JD, Rao SV, Schrier SL, Artz A; Partnership for Anemia: Clinical and Translational Trials in the Elderly Consortium:Renal toxicity associated with salsalate in elderly adults with anemia. J Am Geriatr Soc.2016; 64: 898–899.
23. Chou CI, Shih CJ, Chen YT, Ou SM, Yang CY, Kuo SC, Chu D: Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: A nested case-control cohort study. Medicine (Baltimore)2016; 95: e2645, 2016
24. Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, Lin WC, ChengYP,TsaiTF,HoSY:Increased risk of chronic kidney disease in rheumatoid arthritis associated with cardiovascular complications-anational population-basedcohortstudy.PLoSOne10: e0136508, 2015
25. Dixit M, Doan T, Kirschner R, Dixit N: Significant acute kidney injury due to non-steroidal anti-inflammatory drugs: Inpatient setting. Pharmaceuticals (Basel).2010; 3: 1279–1285.
26. Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL: Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med 26: 285–291, 2015
27. Winkelmayer WC, Waikar SS, Mogun H, Solomon DH: Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med 121: 1092–1098, 200
28. Langman MJ, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. BMJ1985; 290:347–9.
29. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119:521–35.
30. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289:735–41.
31. Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66:76–84.
32. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160:1465–70.
33. Brater DC, Harris C, Redfern JS, et al. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001; 21:1–15.
34. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133:1–9.
35. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954–9.
36. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108:7–13.
37. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289:735–41.
38. Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66:76–84.
39. Brater DC, Harris C, Redfern JS, et al. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001; 21:1–15.
40. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133:1–9.
41. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti- inflammatory drugs on blood pressure. Arch Intern Med 1993; 153:477–84.
42. Guidelines: ACoRSoO. Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee. Arthritis Rheum 2000;43:1905– 15
43. Jordan S, White J. Non-steroidal anti-inflammatory drugs: clinical issues. NursStand. 2001; 15(23):4552.
44. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase2 are associated with human gastrointestinal toxicity: a full in vitro analysis. ProcNatlAcadSci USA. 1999;96(13):7563-8.
45. Jamali F. Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. Eur J Drug Metab Pharmacokinet.1988; 13(1):1-9.
46. Mehvar R, Jamali F. Pharmacokinetic analysis of the enantiomeric inversion of chiral nonsteroidal antiinflammatory drugs. Pharm Research. 1988 Feb;5(2):76-9.
47. Jamali F, Lovlin R, Aberg G. Bi-directional chiral inversion of ketoprofen in CD-1 mice. Chirality. 1997; 9(1):29-31.
48. Poddubnyy D, Song IH, Sieper J. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2009; 27(4 Suppl 55):S148-51
49. McCarberg B, Tenzer P. Complexities in the pharmacologic management of osteoarthritis pain. Current medical research and opinion. 2013 Apr 3.
50. American Society of Hospital P, American Society of Health System P, Teton Data S, Stat!Ref electronic medical l. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists, Inc; 2010.
51. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013 Jun 26; 309(24):2563-71.
52. Cote S, Carmichael PH, Verreault R, Lindsay J, Lefebvre J, Laurin D. Nonsteroidal antiinflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimer's & dementia: J Alzheimer Asso. 2012 May; 8(3):219-26.
53. Arvanitakis Z, Grodstein F, Bienias JL, Schneider JA, Wilson RS, Kelly JF, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology. 2008; 70(23):221925.
54. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Inter. 2012 Jun; 32(6):1491-50
55. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res. 2009 Apr;50 Suppl:S423-8.
56. Harirforoosh S, Jamali F. Renal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8(6):669-81
57. Essex MN, Zhang RY, Berger MF, Upadhyay S,Park PW. Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials. Expert Opin Drug Safety. 2013;12(4):465-77
58. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis. 1996;28(1 Suppl 1):S56-62
59. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010; 24(2):121-32.
60. Davies NM, Longstreth J, Jamali F. Misoprostol therapeutics revisited. Pharmacotherapy. 2001; 21(1):60-73.
61. Coyne KS, Margolis MK, Cappelleri JC, Hsieh R, Essex MN, Park PW, et al. Prevalence of gastroprotective agent (GPA) use in adults with arthritis in the United States. Curr Medical Res Opin. 2013; 29(5):421-33.
62. Le Ray I, Barkun AN, Vauzelle-Kervroedan F, Bardou M. Failure to renew prescriptions for gastroprotective agents to patients on continuous nonsteroidal anti-inflammatory drugs increases rate of upper gastrointestinal injury. Clin Gastroenterol Hepatol. 2013; 11(5): 499-504.
63. Kellner HL, Li C, Essex MN. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. Curr Med Res Opin. 2012 Sep; 28(9):1537-45.
64. Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and nonselective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol. 2013; 48(7):8308.
65. Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2006; 24(5):751-67.
66. De Petris G, Lopez JI. Histopathology of diaphragm disease of the small intestine: a study of 10 cases from a single institution. Am J Clin Pathol. 2008; 130(4):518-25.
67. Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008; 135(5):1517-25.
68. Lake H. Ibuprofen belly: A case of small bowel stricture due to non-steroidal anti-inflammatory drug abuse in the setting of codeine dependence. Aust N Z J Psychiatry. 2013; 47: 1210-1211
69. Harirforoosh S, Jamali F. Renal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8(6):669-81
70. Musu M, Finco G, Antonucci R, Polati E, Sanna D, Evangelista M, et al. Acute nephrotoxicity of NSAID from the foetus to the adult. Eur Review Med Pharmacol Sci. 2011; 15(12):1461-72.
71. Breyer MD, Harris RC. Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens. 2001; 10(1):89-98.
72. Whelton A, Hamilton CW. Nonsteroidal antiinflammatory drugs: effects on kidney function. J Clin Pharmacol. 1991;31(7):588-98
73. Antonucci R, Cuzzolin L, Arceri A, Dessi A, Fanos V. Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur I Clin Pharmacol. 2009; 65(3):223-30
74. Claria J. Cyclooxygenase-2 biology. Curr Pharm Design. 2003; 9(27):2177-90
75. Vonkeman HE, van de Laar MA. Nonsteroidal antiinflammatory drugs: adverse effects and their prevention. Sem Arthritis Rheumat. 2010 Feb;39(4):294-312
76. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Critical care medicine. 2008; 36(4 Suppl):S216-23.
77. Palmer BF. Renal complications associated with use of nonsteroidal anti-inflammatory agents. J Investig Med. 1995; 43(6):516-33.
78. Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther. 2002;72(1):50-61
79. Fernandez-Llama P, Ecelbarger CA, Ware JA, Andrews P, Lee AJ, Turner R, et al. Cyclooxygenase inhibitors increase Na-K-2Cl cotransporter abundance in thick ascending limb of Henle's loop. Am J Physiol. 1999; 277(2 Pt 2):F219-F26.
80. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 2000; 7(3):159-75.
81. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol ExpTher. 1999; 289(2):735-41.
82. Stichtenoth DO, Frolich JC. COX-2 and the kidneys. Curr Pharm Des. 2000; 6(17):1737-53
83. Platts-Mills TF, Richmond NL, Hunold KM, Bowling CB. Life-threatening hyperkalemia after 2 days of ibuprofen. Am J Emerg Med. 2013 Feb; 31(2):465 e1-2.
84. Lam Q, Schneider HG. Hyperkalaemia with cyclooxygenase-2 inhibition and hypoaldosteronism. Inter Med J. 2005; 35(9):572-3.
85. Sturmer T, Erb A, Keller F, Gunther KP, Brenner H. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am J Med. 2001; 111(7):521-7.
86. Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Prac. 2013;30(3):247-55
87. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Review. 2011; 19(4):184-91.
88. Mackenzie IS, MacDonald TM. Treatment of osteoarthritis in hypertensive patients. Expert opin Pharmacothe. 2010; 11(3):393-403.
89. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012; 125(1):14-22.
90. Sudano I, Flammer AJ, Roas S, Enseleit F, Noll G, Ruschitzka F. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep. 2012;14(4):304-9
91. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007 Feb 26; 167(4):394-9
92. Jamali F. Arthritis is associated with cardiovascular disease in the users of analgesics and nonsteroidal anti-inflammatory drugs. Arch Intern Med. 2007;167(21):2371-2;
93. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum.2005; 52(3):722-32.
94. Mayo PR, Skeith K, Russell AS, Jamali F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. B J Clin Pharmacol. 2000;50(6):605-13
95. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal antiinflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141-9.
96. Fosbol EL, Folke F, Jacobsen S, Rasmussen JN, Sorensen R, Schramm TK, et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among healthy individuals. Circulation Cardiovascular quality and outcomes. 2010 Jul;3(4):395-405
97. Renner B, Brune K. Are myocardial infarctions and death in healthy individuals associated with the use of cyclooxygenase inhibitors? Clin Pharmacol Ther. 2009 Dec; 86(6):599-600; author reply 2-4.
98. van Beers EJ, de Groot JR, Tijssen JG. Do NSAIDs actually protect against myocardial infarction and death? Clin Pharmacol Ther. 2009 Dec; 86(6):601-2.
99. Moore N. No obvious extra cardiovascular risk associated with low-dose NSAIDs. Clin Pharmacol ther. 2009 Dec; 86(6):600-1.
100. Fosbol EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190-7
101. Fosbol EL, Folke F, Jacobsen S, Rasmussen JN, Sorensen R, Schramm TK, et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among healthy individuals. Circulation Cardiovascular quality and outcomes. 2010; 3(4):395-405.
102. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated with Nonsteroidal Anti-Inflammatory Drugs in the General Population. J Am Coll Cardiol. 2008; 52(20):1628-36.
103. Varas-Lorenzo C, Castellsague J, Stang MR, PerezGutthann S, Aguado J, Rodriguez LA. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009;18(11):1016-25.
104. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005 Apr 5; 142(7):481-9.
105. Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Brit J Clin Pharmacol.2010;69(6):689-700
106. Kerr SJ, Rowett DS, Sayer GP, Whicker SD, Saltman DC, Mant A. All-cause mortality of elderly Australian veterans using COX-2 selective or nonselective NSAIDs: a longitudinal study. Br J Clin Pharmacol. 2011; 71(6):936-42.
107. Fosbol EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009; 85(2):190-7.
108. Grimaldi-Bensouda L, Rossignol M, Danchin N, Steg PG, Bessede G, Ovize M, et al. Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs. Heart. 2011; 97(22):1834-40.
109. Varas-Lorenzo C, Castellsague J, Stang MR, PerezGutthann S, Aguado J, Rodriguez LA. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009;18(11):1016-25
110. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005 May 9; 165(9):978-84.
111. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: Population based nested casecontrol analysis. Br Med J (Clin Res Ed). 2005; 330(7504):1366-9.
112. Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, Idanpaan-Heikkila JE, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: A nationwide case-control study from Finland. Eur Heart J. 2006; 27(14):1657-63.
113. Reiss AB, Anwar F, Chan ES, Anwar K. Disruption of cholesterol efflux by COXIB medications and inflammatory processes: link to increased cardiovascular risk. J Investig Med. 2009; 57(6):695702.
114. Roumie CL, Choma NN, Kaltenbach L, Mitchel EF, Jr., Arbogast PG, Griffin MR. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009; 18(11):1053-63.
115. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, et al. Myocardial infarction and individual nonsteroidal antiinflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013 Apr 25.
116. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation.2004 May 4; 109(17):2068-73.
117. Vaithianathan R, Hockey PM, Moore TJ, Bates DW. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. Drug Saf. 2009;32(4):335-43
118. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906-13
119. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352(11):1092-102.
120. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-35
121. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005;142(7):481-9
122. Lanas A, Tornero J, Zamorano JL. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010; 69(8):1453-8.
123. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-35
124. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906-13
125. Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2007;16(5):493-503
126. Roumie CL, Choma NN, Kaltenbach L, Mitchel EF, Jr., Arbogast PG, Griffin MR. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009; 18(11):1053-63.
127. Caughey GE, Roughead EE, Pratt N, Killer G, Gilbert AL. Stroke risk and NSAIDs: an Australian population-based study. Med J Austral. 2011; 195(9):525-9.
128. Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Brit J Clin Pharmacol.2010; 69(6):689-700
129. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Brit M J. 2011;342:c7086
130. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf. 2011; 20(12):1225-36.
131. Caughey GE, Roughead EE, Pratt N, Killer G, Gilbert AL. Stroke risk and NSAIDs: an Australian population-based study. Med J Austral. 2011; 195(9):525-9.
132. Haag MDM, Bos MJ, Hofman A, Koudstaal PJ, Breteler MMB, Stricker BHC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med. 2008; 168(11):1219-24.
133. Capone ML, Tacconelli S, Di Francesco L, Petrelli M, Patrignani P. Cardiovascular effects of valdecoxib: Transducing human pharmacology results into clinical read-outs. Expert Opin Drug Saf. 2008; 7(1):29-42.
134. Horbach SJ, Lopes RD, da CGJC, Martini F, Mehta RH, Petracco JB, et al. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med. 2011 Nov; 124(11):1036-42.
135. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, et al. The association between the use of non-steroidal anti-inflammatory drugs and atrial fibrillation: A nationwide case-control study. Inter J Cardiol. 2012; 6.
136. Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sorensen HT. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. Brit Med J. 2011; 343:d3450.
137. Horbach SJ, Lopes RD, da CGJC, Martini F, Mehta RH, Petracco JB, et al. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med. 2011;124(11):1036-42
138. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006; 116(1):4-15.
139. Yu Z, Crichton I, Tang SY, Hui Y, Ricciotti E, Levin MD, et al. Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc Natl Acad Sci U S A.. 2012; 24;109(17):6727-32.
140. Aljadhey H, Tu W, Hansen RA, Blalock SJ, Brater DC, Murray MD. Comparative effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord.2012; 12:93.
141. Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009; 27(4):886-93.
142. White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiolog. 2009; 104(6):840-5
143. Sudano I, Flammer AJ, Roas S, Enseleit F, Noll G, Ruschitzka F. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep. 2012; 14(4):304-9.
144. Jordan S, White J. Non-steroidal anti-inflammatory drugs: clinical issues. NursStand. 2001; 15(23):4552.
145. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase2 are associated with human gastrointestinal toxicity: a full in vitro analysis. ProcNatlAcadSci USA. 1999; 96(13):7563-8.
Statistics
237 Views | 215 Downloads
How to Cite
Puppala, N., & Reddy, G. (2020). Review on Effects of NSAID`S on Different Systems. Asian Journal of Pharmaceutical Research and Development, 8(1), 100-109. https://doi.org/https://doi.org/10.22270/ajprd.v8i1.621